TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03346226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine is given to patients during spinal anesthesia at the dose of 0.5 μg/kg，adjusted the dose to keep BIS between 70-80 until 30 minutes before the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts，adjust the propofol's dose to keep BIS between 70-80 before the end of surgery
Study: NCT04589624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo hpMRI
Study: NCT02210117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo metastasectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo metastasectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo metastasectomy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo nephrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo nephrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo nephrectomy
Study: NCT02593994

Intervention type: DEVICE
Intervention: Onyx Drug Eluting Stent group
Study: NCT01352338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, endoxan, prednisone
Description: dose-finding
Study: NCT02490059

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bronchoscopy
Description: Bronchoscopy for diagnosis of pulmonary nodules
Study: NCT01352338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide, endoxan, prednisone
Description: oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT03203369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART123
Description: Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART123
Description: Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
Study: NCT02998281

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Threshold (IMT)
Description: Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold (IMT)
Description: Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
Study: NCT02264028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [14C]-DK-AH 269 CL, solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-DK-AH 269 CL, drinking solution
Study: NCT03229954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron isomaltoside (Monofer) intravenous infusion
Description: The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (\< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.~If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate(Feroba-YOU) per oral
Description: 160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
Study: NCT01229761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cotrimoxazole prophylaxis
Description: 100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cotrimoxazole placebo
Description: 100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exclusive breastfeeding until 6 months of age
Description: Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: breastfeeding for 12 months
Description: Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
Study: NCT02614716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3090106
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03919383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study: NCT01147224

Intervention type: DRUG
Intervention: Alvesco
Description: This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Study: NCT04163705

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample collection
Description: Routine Laboratory Analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample collection
Description: Routine Laboratory Analysis
Study: NCT03430674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise, questionnaires and blood draws.
Study: NCT02071173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead
Description: The ACUITY X4 leads are intended for chronic left ventricular pacing and sensing. The leads have 3 tip configuration designs (straight tip, short tip spiral, and long tip spiral), which is intended to provide choices for patients with different anatomies.~The RELIANCE 4-FRONT leads are designed for right-side heart applications within the ventricle, atrium, and superior vena cava. It is intended for permanent sensing, pacing, and defibrillation when used with a compatible implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D).~Subjects were allowed to receive both the ACUITY X4 and RELIANCE 4-FRONT lead.
Study: NCT01292928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent implantation
Description: Stent implantation during the index procedure.
Study: NCT01838798

Intervention type: OTHER
Intervention: Baseline activities
Description: Initial consent procedures and baseline data collection.

Intervention type: OTHER
Intervention: Clinical interview with a psychologist
Description: Clinical interview with a psychologist.~This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:~* An inventory of peritraumatic distress symptoms~* A questionnaire on peritraumatic dissociative experiences~* An assessment of related, potential impacts~* The HADS questionnaire

Intervention type: OTHER
Intervention: Telephone interview 2 months after ICU discharge
Description: At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:~* Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ~* An assessment of psychological trauma~* An assessment of potential impacts

Intervention type: OTHER
Intervention: Clinical interview with a psychologist
Description: At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:~* assess cognitive functions~* evaluate clinical symptoms of depression~* assess quality of life~* assess symptoms of post traumatic stress
Study: NCT02833168

Intervention type: OTHER
Intervention: patient-filled questionnaires
Description: All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.

Intervention type: OTHER
Intervention: patient-filled questionnaires
Description: All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.

Intervention type: OTHER
Intervention: patient-filled questionnaires
Description: All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.

Intervention type: DEVICE
Intervention: spiromanometry
Description: Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure

Intervention type: DEVICE
Intervention: spiromanometry
Description: Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure

Intervention type: DEVICE
Intervention: spiromanometry
Description: Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
Study: NCT04223518

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Serum bovine immunoglobulin
Description: Serum bovine immunoglobulin (SBI), also known by the brand name of Enteragam (Proliant Biologicals, Ankeny, Iowa) is derived from bovine serum and classified as a medical food composed of \>90% protein which consists primarily of immunoglobulins (\>50% of IgG) along with other bovine proteins and peptides similar to those commonly consumed by humans in beef products.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydrolyzed Collagen
Study: NCT04461002

Intervention type: OTHER
Intervention: Retrospective analysis
Description: Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).
Study: NCT04720079

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous infiltration of intercostobrachial nerve
Description: Preoperative subcutaneous infiltration of intercostobrachial nerve with 10ml of 0.5% ropivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T2 paravertebral nerve block
Description: Preoperative ultrasound guided T2 paravertebral nerve block with 10ml of 0.5% ropivacaine
Study: NCT02952352

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes Prevention Program
Description: Culturally adapted diabetes prevention program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program
Description: Culturally adapted diabetes prevention program
Study: NCT01788748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bipolar radiofrequency and infrared

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bipolar radiofrequency and infrared

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional bipolar radiofrequency

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional bipolar radiofrequency
Study: NCT00574587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (if HER2-positive) 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical excision of tumor from breast
Study: NCT02189551

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training with Lokomat Pro

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait training with Lokomat Pro FreeD
Study: NCT05368779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The internet-based psychosocial intervention
Description: Participants were provided psychoeducation on intimate partner abuse, psychological trauma, Social Learning Theory, and Cognitive Behavioral Therapy methods. Intimate partner abuse and psychological trauma were discussed in the context of sociocultural factors. Cognitive Behavioral Therapy approaches were used to attempt to normalize intimate partner abuse, psychological trauma and their effects on participants. Participants were exposed to trauma gradually with record of sessions watching and imaginary exposure methods for reducing avoidance behaviours. Schemas, intermediate beliefs, and automatic thoughts of participants were studied using Cognitive Behavioral Therapy approaches and cognitive restructuring was fulfilled. The universality of mental pain, the meaning of life, the integrate trauma into life histories of participants, expectations for the future romantic relationships, and post traumatic growth were all discussed in accordance with the goals and values of participants.
Study: NCT01692782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-225289
Description: SEP-225289 4mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-225289
Description: SEP-225289 8mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT01945606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (treatment 1)
Description: Oral administration of placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1067197 (treatment 2)
Description: Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
Study: NCT02046330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation Model 3387 Model 3389
Description: Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
Study: NCT02769286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
Study: NCT03686852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: same medications but different dosages
Description: The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A), 150IU (Group B) or 250IU (Group C) of recFSH (Puregon®, MSD)
Study: NCT02490059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bronchoscopy
Description: Bronchoscopy for diagnosis of pulmonary nodules
Study: NCT01717456

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily diary
Description: Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
Study: NCT01717456

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily diary
Description: Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protective pads or garments
Description: In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Protective pads or garments
Description: In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
Study: NCT04013256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette Smoke
Description: Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoke
Description: Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoke
Description: Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
Study: NCT03391674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation through oral capsules after omeprazole pre-treatment
Study: NCT01016210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuveris
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuveris
Description: All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
Study: NCT04149405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 periodontal therapy
Description: Scaling and root planning with ultrasonic and hand instruments under local anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phase 1 periodontal therapy
Description: Scaling and root planning with ultrasonic and hand instruments under local anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonate therapy
Description: Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonate therapy
Description: Using aclasta: intravenous infusion of 5 mg of zoledronic acid once a year
Study: NCT00952367

Intervention type: OTHER
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab
Study: NCT00195910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.1 mg/kg IV morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 0.015 mg/kg IV hydromorphone
Study: NCT04161508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injection
Description: injection of sugammadex for the reversal of neuromuscular blockade at the end of the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine Injection
Description: injection of neostigmine for the reversal of neuromuscular blockade at the end of the surgery
Study: NCT02871648

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone
Description: Fludrocortisone 0.1 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Epleronone 100 mg
Study: NCT00898885

Intervention type: PROCEDURE
Intervention: oral biopsy
Description: oral mucosa and salivary gland biopsy after bone marrow transplantation